AC
UTHR icon

Ascend Capital’s United Therapeutics UTHR Stock Holding History

Ascend Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-51,973
Closed -$5.5M – 166
2016
Q2 		$5.5M Buy
+51,973
New +$5.8M 0.36% 90
2015
Q3 		– Sell
-16,334
Closed -$2.84M – 172
2015
Q2 		$2.84M Sell
16,334
-23,950
-59% -$4.31M 0.09% 125
2015
Q1 		$6.95M Buy
+40,284
New +$6.14M 0.24% 101
2014
Q2 		– Sell
-180,000
Closed -$16.9M – 217
2014
Q1 		$16.9M Buy
+180,000
New +$18.4M 0.44% 68

Other funds holding UTHR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ascend Capital's UTHR Position: Q3 2016 in Review

Ascend Capital sold out of United Therapeutics (UTHR) in Q3 2016, closing a stake of 51,973 shares — an estimated $5.5M sold.

Ascend Capital first reported a position in UTHR in Q1 2014 and held it in 4 quarters. The position peaked at $16.9M in Q1 2014. 394 funds tracked by Wall St. Rank hold UTHR as of Q3 2016.

  • Ascend Capital reported no remaining United Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Ascend Capital sold 51,973 United Therapeutics shares in Q3 2016, an estimated $5.5M.
  • Ascend Capital first reported a position in United Therapeutics in Q1 2014 and held it in 4 quarters.
  • Ascend Capital's United Therapeutics position peaked at $16.9M in Q1 2014.
  • 394 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2016.

Based on Ascend Capital's 13F filing for Q3 2016, filed 14 Nov 2016.